Calcium ketovaline as new therapy for uremic hyperphosphatemia.

Abstract

Since treatment of uremic hyperphosphatemia still represents a major problem and phosphate-binding agents carry the well-known risk of aluminum intoxication, we carried out a study to determine whether calcium ketovaline, a keto acid containing calcium, would show phosphate-binding effects comparable to those obtained with a mixture of amino acids and calcium salts of ketoanalogues tested previously. In vitro as well as in vivo studies show convincingly that calcium ketovaline is a valuable intestinal phosphate binder. Dialysis patients treated for 6 weeks showed a significant (p less than 0.05) decrease in serum phosphate from 2.36 +/- 0.19 to 1.81 +/- 0.16 mmol/l.

• Authors: K Schaefer, D von Herrath, C M Erley, G Asmus
• Journal: Mineral and electrolyte metabolism (Miner Electrolyte Metab) Vol. 16 Issue 6 Pg. 362-4 ( 1990) ISSN: 0378-0392 [Print] Switzerland
• PMID: 2089249 (Publication Type: Journal Article)

Chemical References

• Hemiterpenes
• Keto Acids
• Phosphates
• alpha-ketoisovalerate

Topics

• Hemiterpenes
• Humans
• In Vitro Techniques
• Keto Acids (therapeutic use)
• Phosphates (blood)
• Renal Dialysis
• Uremia (complications, drug therapy)